Domača stranHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Prejšnji trg. dan.
25,85 €
Dnevni razpon
25,67 € - 25,67 €
Letni razpon
19,52 € - 36,69 €
Tržna kapitalizacija
3,58 mrd. USD
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | mar. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | — | — |
Stroški poslovanja | 126,19 mio. | 28,63 % |
Čisti dohodek | −125,30 mio. | −357,42 % |
Čista dobičkovnost prihodkov | — | — |
Earnings per share | −1,02 | −326,67 % |
EBITDA | −121,67 mio. | −339,34 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | mar. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 520,91 mio. | 8,30 % |
Skupna sredstva | 955,15 mio. | 7,16 % |
Skupne obveznosti | 459,74 mio. | 7,87 % |
Celoten lastniški kapital | 495,40 mio. | — |
Shares outstanding | 124,20 mio. | — |
Razmerje P/B | 6,63 | — |
Donosnost sredstev | −39,90 % | — |
Donosnost kapitala | −43,18 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | mar. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −125,30 mio. | −357,42 % |
Denar iz dejavnosti | −92,38 mio. | −191,68 % |
Denar iz naložb | −268,94 mio. | −645,70 % |
Denar iz financiranja | 430,78 mio. | 82.741,73 % |
Neto sprememba denarnih sredstev | 69,49 mio. | 203,27 % |
Prost denarni tok | −91,82 mio. | −262,49 % |
Vizitka
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Generalni direktor
Datum ustanovitve
1. jan. 2004
Sedež organizacije
Spletno mesto
Zaposleni
525
